BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Beijing Biotech BCMA/GPRC5D dual-target CAR-T readouts · Asse
 tMemo
X-WR-CALDESC:Upcoming readouts of Beijing Biotech BCMA/GPRC5D dual-target C
 AR-T\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07523555-3376@assetmemo.bio
DTSTAMP:20261121T010845Z
DTSTART;VALUE=DATE:20270314
DTEND;VALUE=DATE:20270315
SUMMARY:Beijing Biotech BCMA/GPRC5D dual-target CAR-T: Phase 1/2 readout es
 t. (NCT07523555)
DESCRIPTION:Beijing Biotech BCMA/GPRC5D dual-target CAR-T\, phase 1/2\, Mul
 tiple Myeloma.\nStudy: Adaptive Dual-Target CAR-T Cells for Relapsed or Re
 fractory Hematologic Malignancies\nEstimated primary completion: 14 March 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/beijing-biotech
 -bcma-gprc5d-dual-target-car-t#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07523555
URL:https://assetmemo.bio/drug/beijing-biotech-bcma-gprc5d-dual-target-car-
 t#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
